【瞩目】东阳光药入局大涨82%潜力注射剂

米内网02-11

精彩内容日前，CDE官网显示，乳源东阳光药业的注射用硫酸艾沙康唑以仿制4类报产获受理。米内网数据显示，注射用硫酸艾沙康唑在2024年中国三大终端六大市场销售额近2亿元，2025年Q1-Q3同比增长82.17%，是全身用抗真菌化药注射剂TOP5产品。来源：米内网一键检索注射用硫酸艾沙康唑是一种广谱三唑类抗真菌药物，主要用于治疗侵袭性曲霉病和毛霉病等严重真菌感染。近年中国三大终端六大市场注射用硫酸...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610961025?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-11 16:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610961025","market":"hk","top_or_hot":-1,"title":"【瞩目】东阳光药入局大涨82%潜力注射剂","media":"米内网","content":"<div>\n<p>精彩内容日前，CDE官网显示，乳源东阳光药业的注射用硫酸艾沙康唑以仿制4类报产获受理。米内网数据显示，注射用硫酸艾沙康唑在2024年中国三大终端六大市场销售额近2亿元，2025年Q1-Q3同比增长82.17%，是全身用抗真菌化药注射剂TOP5产品。来源：米内网一键检索注射用硫酸艾沙康唑是一种广谱三唑类抗真菌药物，主要用于治疗侵袭性曲霉病和毛霉病等严重真菌感染。近年中国三大终端六大市场注射用硫酸...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211181552a6ee8cda&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【瞩目】东阳光药入局大涨82%潜力注射剂</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【瞩目】东阳光药入局大涨82%潜力注射剂\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-11 16:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211181552a6ee8cda&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容日前，CDE官网显示，乳源东阳光药业的注射用硫酸艾沙康唑以仿制4类报产获受理。米内网数据显示，注射用硫酸艾沙康唑在2024年中国三大终端六大市场销售额近2亿元，2025年Q1-Q3同比增长82.17%，是全身用抗真菌化药注射剂TOP5产品。来源：米内网一键检索注射用硫酸艾沙康唑是一种广谱三唑类抗真菌药物，主要用于治疗侵袭性曲霉病和毛霉病等严重真菌感染。近年中国三大终端六大市场注射用硫酸...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211181552a6ee8cda&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06887","symbol_name":"东阳光药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211181552a6ee8cda&s=b","article_id":"2610961025","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211181552a6ee8cda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610961025","pubTimestamp":1770797033,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容日前，CDE官网显示，乳源东阳光药业的注射用硫酸艾沙康唑以仿制4类报产获受理。米内网数据显示，注射用硫酸艾沙康唑在2024年中国三大终端六大市场销售额近2亿元，2025年Q1-Q3同比增长82.17%，是全身用抗真菌化药注射剂TOP5产品。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06887":"东阳光药","BK1191":"制药"},"translate_title":"[Attention] Dongyang Sunshine Pharmaceuticals entered the market and surged 82% potential injections","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06887":1.5},"content_text":"精彩内容日前，CDE官网显示，乳源东阳光药业的注射用硫酸艾沙康唑以仿制4类报产获受理。米内网数据显示，注射用硫酸艾沙康唑在2024年中国三大终端六大市场销售额近2亿元，2025年Q1-Q3同比增长82.17%，是全身用抗真菌化药注射剂TOP5产品。来源：米内网一键检索注射用硫酸艾沙康唑是一种广谱三唑类抗真菌药物，主要用于治疗侵袭性曲霉病和毛霉病等严重真菌感染。近年中国三大终端六大市场注射用硫酸艾沙康唑销售情况（单位：万元）来源：米内网格局数据库注射用硫酸艾沙康唑在近年中国三大终端六大市场（统计范围见文末）销售规模快增长，2024年接近2亿元，2025年Q1-Q3同比增长82.17%，是全身用抗真菌化药注射剂TOP5产品。米内网数据显示，注射用硫酸艾沙康唑已有16家企业拥有生产批文，成都天台山制药、海南金瑞宝医药、上海宣泰医药等15家企业过评，乳源东阳光药业、天津红日药业、石药欧意药业等31家企业均以仿制4类报产在审，获批后视同过评。东阳光药2025年至今报产在审产品来源：米内网中国申报进度（MED）数据库2025年至今，东阳光药有4款产品报产在审，涵盖全身用抗真菌药、精神安定药、糖尿病用药等治疗亚类。其中，布瑞哌唑在2024年全球销售额是20亿美元级别重磅品种，德谷门冬双胰岛素注射液在2024年中国三大终端六大市场是10亿元级别大品种。来源：CDE官网、米内网数据库等","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610961025","isCrawlerRequest":true}